Chunyu Xu
YOU?
Author Swipe
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Protein arginine methyltransferases (PRMT) are a widely expressed class of enzymes responsible for catalyzing arginine methylation on numerous protein substrates. Among them, type I PRMTs are responsible for generating asymmetric dimethyla…
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Data from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Protein arginine methyltransferases (PRMT) are a widely expressed class of enzymes responsible for catalyzing arginine methylation on numerous protein substrates. Among them, type I PRMTs are responsible for generating asymmetric dimethyla…
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Figure from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses Open
Supplementary Table from Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell–Mediated Antitumor Immune Responses
View article: Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Autophagy activity regulated by the PI3K pathway plays a critical role in T cell-induced tumor apoptosis.
View article: Supplementary Figure S6 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S6 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
The effect of PI3Kbeta inhibitor on melanoma with PTEN loss.
View article: Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
T cell–mediated immunotherapies are promising cancer treatments. However, most patients still fail to respond to these therapies. The molecular determinants of immune resistance are poorly understood. We show that loss of PTEN in tumor cel…
View article: Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
List of genes which are differentially expressed in melanomas with PTEN loss.
View article: Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S4 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
List of genes which are differentially expressed in melanomas with PTEN loss.
View article: Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Supplementary Table S1. Patient characteristics of the single-agent anti-PD-1 cohort. Supplementary Table S2. List of primers used for gene expression analysis by real-time PCR. Supplementary Table S3. List of autophagy-related genes for o…
View article: Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Lymphocyte infiltration status and the expression level of MHC class I in tumors from patients with melanoma.
View article: Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S2 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Lymphocyte infiltration status and the expression level of MHC class I in tumors from patients with melanoma.
View article: Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Examples of increased VEGF expression in regions with loss of PTEN in melanoma patients with heterogeneous PTEN expression.
View article: Supplementary Figure S1 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S1 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
PTEN loss in melanoma promotes resistance to T cell-mediated anti-tumor activity in the context of concurrent a selective inhibitor for mutant BRAF.
View article: Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Improved antitumor activity can be achieved by combining the PI3Kbeta inhibitor and immune checkpoint blockers.
View article: Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Methods, Figure Legends, Tables S1 - S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Supplementary Table S1. Patient characteristics of the single-agent anti-PD-1 cohort. Supplementary Table S2. List of primers used for gene expression analysis by real-time PCR. Supplementary Table S3. List of autophagy-related genes for o…
View article: Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S7 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Improved antitumor activity can be achieved by combining the PI3Kbeta inhibitor and immune checkpoint blockers.
View article: Supplementary Figure S6 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S6 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
The effect of PI3Kbeta inhibitor on melanoma with PTEN loss.
View article: Supplementary Figure S1 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S1 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
PTEN loss in melanoma promotes resistance to T cell-mediated anti-tumor activity in the context of concurrent a selective inhibitor for mutant BRAF.
View article: Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S3 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Examples of increased VEGF expression in regions with loss of PTEN in melanoma patients with heterogeneous PTEN expression.
View article: Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Supplementary Figure S5 from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
Autophagy activity regulated by the PI3K pathway plays a critical role in T cell-induced tumor apoptosis.
View article: Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Data from Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Open
T cell–mediated immunotherapies are promising cancer treatments. However, most patients still fail to respond to these therapies. The molecular determinants of immune resistance are poorly understood. We show that loss of PTEN in tumor cel…